Jubilant Life Sciences' manufacturing facility at Montreal, Canada, has got a clean chit from the US Food and Drug Administration (US FDA).
The facility, which had come under the American regulatory scanner after it received a warning letter last February, has resolved issues and has been been classified as 'acceptable' by the US FDA, Jubilant Life said in a statement.
"This resolves all issues raised by the FDA on the facility in February 2013 and subsequent communications", the statement said.
According to the statement, US FDA re-inspected Jubilant's Montreal facility in September 2013 and reviewed its responses before giving it a clean chit.
Jubilant Life Sciences manufactures and supplies active pharmaceutical ingredient (API), generics, specialty pharmaceuticals and life science ingredients. It also provides services in contract manufacturing and drug discovery and development. The company has 10 manufacturing facilities spread across India, the US and Canada.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)